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PrognosisAbstract Introduction: In view of recent therapeutic breakthroughs in acute coronary syn-
dromes (ACS) and essential demographic and socioeconomic changes in Greece, we conducted
the prospective, multi-center, nationwide PHAETHON study (An Epidemiological Cohort Study
of Acute Coronary Syndromes in the Greek Population) that aimed to recruit a representative
cohort of ACS patients and examine current management practices and patient prognosis.
Methods: The PHAETHON study was conducted from May 2012 to February 2014. We enrolled
800 consecutive ACS patients from 37 hospitals with a proportional representation of all types
of hospitals and geographical areas. Patients were followed for a median period of 189 days.
Outcome was assessed with a composite endpoint of death, myocardial infarction, stroke, ur-
gent revascularization and urgent hospitalization for cardiovascular causes.
Results: Themean age of patients was 62.7 years (78%males). Themajority of patients (nZ411,
51%) presented with ST-elevation myocardial infarction (STEMI), whereas 389 patients pre-
sented with NSTEMI (nZ303, 38%) or UA (nZ86, 11%). Overall, 58.8% of the patients had hyper-
tension, 26.5% were diabetic, 52.5% had dyslipidemia, 71.1% had a smoking history (current or
past), 25.8% had a family history of coronary artery disease (CAD) and 24.1% had a prior history
of CAD. In STEMI patients, 44.5% of patients were treated with thrombolysis, 38.9% underwent a
coronary angiogram (34.1% were treated with primary percutaneous coronary intervention) and
16.5% did not receive urgent treatment. The pain-to-door time was 169 minutes. During hospi-
talization, 301 (38%) patients presented one or more complications, and 13 died (1.6%). During
follow-up, 99 (12.6%) patients experienced the composite endpoint, and 21 died (2.7%).
Conclusions: The PHAETHON study provided valuable insights into the epidemiology, manage-
ment and outcome of ACS patients in Greece. Management of ACS resembles the management
observed in other European countries. However, several issues still to be addressed by public
authorities for the timely and proper management of ACS.
ª 2016 Hellenic Cardiological Society. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute coronary syndromes (ACS) represent a challenging
and demanding clinical problem. ACS comprise the majority
of all acute medical admissions and encompass a high risk
of in-hospital morbidity and mortality. Despite significant
improvements in morbidity and mortality through the
enhancement of treatment modalities in recent years, pa-
tients with ACS remain at high risk of recurrent ischemic
events and death. These facts underscore the importance
of proper and concise documentation of contemporary
management and ACS prognosis at both international and
national levels.1
Numerous epidemiological studies from European coun-
tries have led to insights regarding the prevalence, treat-
ment and prognosis of ACS in Europe. These studies have
also indicated geographic differences, disparities in dietary
habits and the prevalence of cardiovascular risk factors andheterogeneity in the care and prognosis of patients with
ACS across Europe.2 Therefore, national surveys are
thought to be indispensable to the epidemiology, treatment
and prognosis of the everyday patient population.
Furthermore, these surveys should incorporate a nation-
wide representative population and hospital sample to
reflect everyday practice on ACS. Representativeness is of
utmost importance, especially in countries with great di-
versity in geography and healthcare infrastructure, such as
Greece. Nationwide surveys also comprise a pragmatic
assessment of ACS management, rather than a highly
controlled clinical setting, as the one utilized in random-
ized studies.1
During the previous decade, the findings of the pro-
spective survey named GREECS12 and the results of a large
countrywide survey in Greece, the HELIOS study,3 were
published in 2005 and 2007, respectively.3 However, in
subsequent years, much has changed both in the
Epidemiology of ACS in Greece 159prevalence and management of ACS. Therefore, we con-
ducted the PHAETHON study, an up-to-date sequel of the
HELIOS study. The PHAETHON study aimed prospectively to
provide further contemporary data concerning the epide-
miological profile, management pattern and outcomes in a
cohort of real-word, consecutive ACS patients included in a
countrywide observational study in Greece.
2. Methods
2.1. Study population
The PHAETHON study was a prospective, multicenter,
observational study that enrolled consecutive patients
with a hospital discharge diagnosis of ACS [ST-elevation
myocardial infarction (STEMI), non-ST elevation myocar-
dial infarction (NSTEMI), unstable angina (UA)] at a total of
37 participating centers in Greece. The study was con-
ducted from May 2012 to February 2014. Case definition
was based on the 2012 consensus definition of myocardial
infarction4 and relevant European Guidelines.5,6 To mini-
mize systematic enrollment bias and to maximize the
generalizability of our results, we recruited patients from
centers with a representative geographical distribution,
proportionally covering all regions in Greece. The majority
of ACS patients are initially hospitalized in the cardiology
departments of regional hospitals, and assuming that the
number of ACS is proportional to the resident population
older than 25 years in every geographical distribution, we
calculated a certain number of consecutive ACS patients
to be enrolled in the survey from each region, in propor-
tion to the estimated population older than 25 years in
each of the major geographical regions (Fig. 1). Further-
more, to avoid the caveat of overrepresentation of hos-
pitals with catheterization facilities, we balanced patientFigure 1 Geographical distribution of the participating centers a
geographical region.inclusion from centers with and without revascularization
capacity and other hospital characteristics (public and
private, academic and non-academic, rural and urban
hospitals). All patients were informed about the study and
signed a written informed consent. The study was con-
ducted according to the Declaration of Helsinki, the Eu-
ropean Guidelines on Good Clinical Practice, and relevant
national and regional authority requirements and ethics
committees.
2.2. Measured variables
During hospitalization, a case report form was filled out for
patients with a confirmed diagnosis of ACS. The case report
included data on demographic (age, gender, height,
weight, waist circumference, body mass index [BMI],
educational level, marital and employment status), clinical
(presentation and time of symptom onset, the selected
means and duration of transportation to the hospital,
medications used before admission), and electrocardio-
graphic characteristics of the patients. All patients were
questioned about their past medical cardiovascular and
non-cardiovascular history and the prevalence of the
following cardiovascular risk factors: hypertension (blood
pressure 140/90 mmHg or treatment with antihyperten-
sive agents), dyslipidemia (total cholesterol 190 mg/dL or
treatment with hypolipidemic medications), diabetes mel-
litus, smoking status (history of smoking was established in
current or ex-smokers), and family history of premature
coronary artery disease (CAD). Metabolic syndromes were
identified based on ATP III criteria. Data collection was
based on standardized definitions.7 Moreover, the case
report included diagnostic and treatment modalities, in-
hospital complications, and discharge status. Further-
more, we calculated the (Global Registry of Acute Coronarynd table with the number of participating patients from each
160 G. Andrikopoulos et al.Events) GRACE risk score for risk stratification of patients
upon admission.8,9
The primary outcome of the study was the assessment of
epidemiological characteristics, management and in-
hospital mortality of ACS patients in Greece. The second-
ary outcome variable was the early prognosis (6 months) of
ACS patients, which was investigated through a composite
endpoint consisting of cardiovascular death, myocardial
infarction, stroke/transient ischemic attack, urgent reper-
fusion [percutaneous coronary intervention (PCI) or coro-
nary artery bypass graft (CABG)] and urgent hospitalization
due to cardiovascular causes. All patients were contacted
by means of questionnaires or telephone interview. Data
were confirmed and verified against hospital databases and
medical records.
2.3. Statistical analysis
Continuous variables are presented as the mean  SD,
whereas non-normally distributed variables are presented
as medians and interquartile ranges. We used Student’s t
tests for independent samples to compare means for nor-
mally distributed variables, Mann-Whitney tests for skewed
variables and chi-square tests for qualitative variables. The
Shapiro-Wilk test for normality was used to evaluate the t-
test assumption. The natural logarithm of the time from
symptoms to first medical contact was used because of its
skewed distribution. A p value<0.05 was considered to be
significant. Data analysis was performed using SPSS soft-
ware, version 20.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Patient population and initial presentation
We recruited 800 patients (mean ageZ62.713.0 years,
78.3% men). Regarding their diagnosis, the majority of pa-
tients (nZ411, 51.38%) presented with ST-elevation
myocardial infarction (STEMI), whereas 389 patients pre-
sented as NSTEMI (nZ303, 37.88%) or UA (nZ86, 10.75%). InTable 1 Baseline characteristics according to acute coronary s
Variable STEMI
Age (years) 6112




Family history of CAD 105 (2
History of CAD 57 (13
Smokers (past or current) 308 (7
Body mass index (kg/m2) 28.24
Waist (cm)* 101.4
Metabolic syndrome* 178 (5
Probability of in-hospital mortality based on GRACE (%){ 2.25 (1
Probability of 6-month mortality based on GRACE (%){ 3.17 (1
*nZ684, {nZ682.
STEMIZST-elevation myocardial infarction, NSTEMIZNon-ST elevati
Artery Disease.Table 1, we report the baseline characteristics of patients
in each ACS category. STEMI patients were younger
(p<0.001) and had increased prevalence of smoking history
(pZ0.034) compared with non-STEMI and UA patients;
however, no difference was found based on gender.
Regarding cardiovascular risk factors, STEMI patients had
less probability of having hypertension, hypercholester-
olemia, diabetes, metabolic syndrome and history of
confirmed CAD compared with other ACS categories; how-
ever, the prevalence of family history of CAD was not
significantly different between ACS categories (Table 1).
The majority of patients presented with chest pain
(nZ713, 89.1%). However, the patients also presented with
one or more other symptoms such as chest discomfort
radiating to arms, neck or jaw (nZ461, 57.6%), nausea/
vomiting (nZ227, 28.4%), sweating (nZ452, 56.5%), dizzi-
ness (nZ182, 22.8%) or dyspnea (nZ234, 29.3%).
The median duration between symptom onset and first
medical contact (FMC), which is defined as the time of
diagnostic electrocardiogram or the ambulance arrival,
was equal to 169 min (IQR: 60e446 min), whereas the
median duration of transfer to the hospital was 30 min
(IQR: 15e45 min) for those patients (48%) who were
transferred by emergency medical system (EMS, ambu-
lance or helicopter) compared with 15 min (IQR: 10e30)
for those (52%) who were transferred on their own means
(taxi or car).
3.2. Management of STEMI patients
Most patients with STEMI were treated with thrombolysis
(nZ183, 44.5%), principally with tenecteplase (nZ91,
49.7%) and reteplase (nZ82, 44.8%). The median door-to-
needle time was 30 min (IQR: 19e60). Thrombolysis was
considered successful in more than four out of five STEMI
patients (nZ149, 81.4%). A small percentage (nZ40, 26.8%)
of the patients also underwent a coronary angiogram. In
contrast, of 34 patients with unsuccessful thrombolysis, the
majority of the patients (nZ20, 58.8%) underwent coronary
catheterization.yndrome type at hospital admission.
(nZ411) Non-STEMI (nZ303) UA (nZ86) p-value
6513 6311 0.001
.6%) 231 (76.2%) 68 (79.1%) 0.557
3.3%) 195 (64.5%) 57 (66.2%) 0.003
7.3%) 171 (56.8%) 56 (66.6%) 0.002
.3%) 108 (36.3%) 21 (24.7%) <0.001
5.7%) 73 (24.4%) 28 (32.5%) 0.282
.9%) 99 (33.0%) 36 (41.8%) <0.001
4.9%) 200 (66.0%) 61 (70.9%) 0.034
.8 28.55.1 28.14.5 0.914
13.8 102.413.8 99.512.8 0.257
3%) 184 (68%) 41 (53%) <0.001
.25e4.18) 2.36 (1.22e4.76) 0.80 (0.49e1.37) <0.001
.77e5.66) 5.32 (2.55e9.70) 2.37 (1.48e4.80) <0.001
on myocardial infarction, UAZunstable angina, CADZCoronary
Table 2 In-hospital events.
Event n, (%)
Death 13 (1.63%)
Angina recurrence 122 (15.3%)
Re-infarction 9 (1.1%)
Heart Failure (defined as >Killip 1) 92 (11.5%)
Pulmonary edema (Killip 3) 38 (4.8%)
Cardiogenic shock (Killip 4) 23 (2.9%)
Mechanic complications 2 (0.3%)
Asystolic arrest 9 (1.1%)
Pulseless electrical activity 5 (0.6%)
2nd/3rd degree AV block 19 (2.4%)
Non Sustained Ventricular Tachycardia 67 (8.4%)
Sustained Ventricular Tachycardia 13 (1.6%)
Ventricular Fibrillation 28 (3.5%)
Atrial Fibrillation/flutter 52 (6.5%)
Stroke/TIA 4 (0.5%)
Major hemorrhagic event (TIMI) 2 (0.3%)
Urgent CABG 5 (0.6%)
LV thrombus 3 (0.4%)
Pericarditis 1 (0.1%)
AVZAtrioventricular, TIAZTransient Ischemic attack,
CABGZCoronary artery bypass graft, TIMIZThrombolysis In
Myocardial Infarction.
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raphy (nZ160, 38.9%), and 140 (34.1%) of them also un-
derwent primary PCI. The median door-to-balloon time was
90 min (IQR: 45e135). For the remaining 20 patients, 1
underwent rescue PCI, 8 underwent elective PCI and 11 did
not undergo any PCI. In most cases, the femoral approach
was preferred (nZ125, 78.1%) compared with the radial
approach (nZ32, 20%).
To ensure reliable estimates of average PCI-related de-
lays at an individual participating hospital, inclusion in this
analysis required a minimum number of STEMI patients.
Specifically, at least 10 STEMI patients during the study,
including at least 5 patients treated with primary PCI and 5
with fibrinolytic therapy, were required. These criteria
yielded 4 hospitals that were eligible for analysis. A given
hospital’s PCI-related delay or its median time delay in
performing primary PCI compared with administering fibri-
nolytic therapy was calculated by subtracting the median
door-to-needle time from the median door-to-balloon time
at each hospital. Finally, the mean median PCI-related time
delay was estimated at 56.2 minutes.
In 68 STEMI (16.5%) patients, no immediate revasculari-
zation treatment was applied, and in several cases, more
than one reason was reported. Regarding thrombolysis,
delayed hospital admission was the most common reason
(nZ43, 63.2%), followed by age (nZ17, 25%), active
bleeding or prone to bleeding status (nZ4, 5.9%), history of
intracranial hemorrhage or intracranial disease or ischemic
attack (nZ2, 2.9%) and suspected aortic dissection (nZ1,
1.5%), while in 9 cases, no apparent reason was reported
(nZ9, 13.2%). Regarding coronary angiography or PCI, un-
availability was the most common reason (nZ60, 88.2%),
followed by delayed hospital admission (nZ14, 20.6%) and
increased risk of complications (nZ4, 5.9%).
3.3. Management of NSTEMI/UA patients
In total, 151 (39%) patients with NSTEMI/UA underwent a
coronary angiogram in the hospital that the patients were
initially admitted or were transferred to another hospital
for coronary angiography, and 92 of the patients (24%) un-
derwent PCI. The median time from admission to coronary
angiography was 43.5 hours (IQR: 13.0e84.0). The remain-
ing patients did not undergo coronary angiography during
hospitalization (nZ238, 61%). The femoral approach was
preferred (nZ108, 71.5%) compared with the radial
approach (nZ27, 17.9%), whereas in the remaining pa-
tients, relevant data were not reported.
A small proportion (nZ19, 4.9%) of patients who were
admitted to the hospital with NSTEMI/UA underwent stress
testing, primarily a treadmill stress test (nZ15) and a
single-photon emission computed tomography imaging test
(nZ4); however, none of the patients underwent a stress
echo. In 12 cases, the stress test showed ischemia or a high
likelihood of ischemia; in 5 cases, the test was negative;
and in 2 cases, the results were not reported.
3.4. In-hospital complications
In total, the in-hospital events are presented in Table 2.
During the hospitalization of 301 (38%) patients, at leastone in-hospital event occurred, and 13 patients (1.63%)
with ACS died. STEMI patients had a higher incidence of in-
hospital complications compared with NSTEMI/UA patients.
Specifically, during hospitalization, more STEMI patients
compared with NSTEMI/UA had heart failure (16% vs 7%,
p<0.001), cardiogenic shock (4% vs 2%, pZ0.028), asystole
(2% vs 0%, pZ0.024), pulseless electrical activity (1% vs 0%,
pZ0.029), 2nd/3rd degree atrio-ventricular block (3% vs 1%,
pZ0.049), non-sustained ventricular tachycardia (14% vs
2%, p<0.001), sustained ventricular tachycardia (3% vs 0%,
pZ0.003), and ventricular fibrillation (6% vs 1%, p<0.001).
No statistically significant differences were found between
the 2 groups in the remaining list of complications,
including death.
3.5. Hospital discharge
In total, 787 patients were discharged. Of the 714 patients
with MI (STEMI or NSTEMI), and according to the interna-
tional definition of MI (nZ670), the majority was classified
as type 1 (nZ619, 92%) followed by type 2 (nZ44, 7%) and
type 4b (nZ7, 1%). The median duration of hospitalization
in the Coronary Care Unit was 3 days (IQR: 2e4). The me-
dian duration of hospitalization was 5 days (IQR: 3.4e6.7).
A significant proportion of the discharged patients (nZ205,
26.0%) was referred to another hospital for further
treatment.
Regarding the New York Heart Association (NYHA) clas-
sifications at hospital discharge, the majority of the pa-
tients were at NYHA I (nZ578, 73.4%), followed by NYHA II
(nZ155, 19.7%), NYHA III (nZ18, 2.3%) and NYHA IV (nZ4,
0.5%). Based on the estimated ejection fraction (EF) by
echocardiography according to the Simpson rule, 88 (11.2%)
Table 3 Medication at hospital discharge (nZ787) and at follow-up (nZ767).
At hospital discharge N (%) At follow-up N (%)
Anti-hypertensive drugs/Anti-arrhythmic drugs
Beta-blockers 676 (85.9%) 646 (84.2%)
Calcium channels blockers 82 (10.4%) 90 (13%)
Nitrates 264 (33.5%) 108 (14.1%)
Aldosterone receptor blockers 92 (11.7%) 81 (10.6%)
Angiotensin converting enzyme inhibitors 397 (50.4%) 327 (42.6%)
Angiotensin receptor II blockers 159 (20.2%) 183 (23.9%)
Other anti-hypertensive drugs 9 (1.1%) 9 (1.2%)
Anti-arrhythmic drugs 33 (4.2%) 23 (3.0%)
Digitalis 9 (1.1%) 7 (0.9%)
Diuretics 178 (22.6%) 190 (24.8%)
Ivabradine 38 (4.8%) 30 (3.9%)
Anti-diabetic drugs
Insulin 60 (7.6%) 42 (5.5%)
Per os anti-diabetic drugs 129 (16.4%) 122 (15.9%)
Anticoagulants/Antiplatelets
Vitamin K antagonists 34 (4.3%) 47 (6.1%)
Dabigatran 1 (0.1%) 1 (0.1%)
Rivaroxaban 0 (0%) 0 (0%)
Low-molecular weight heparin 66 (8.4%) 2 (0.3%)
Aspirin 741 (94.2%) 700 (91.3%)
Clopidogrel 535 (68.0%) 483 (63.0)
Prasugrel 49 (6.2%) 44 (5.7%)
Ticagrelor 133 (16.9%) 110 (14.3%)
Triflusal 10 (1.6%) 6 (0.8%)
Hypolidemic drugs
Statins 759 (96.4%) 710 (92.6%)
Ezetimibe 33 (4.2%) 32 (4.2%)
Niacin 2 (0.3%) 1 (0.1%)
Fibrates 2 (0.3%) 7 (0.9%)
Omega-3 91 (11.6%) 38 (5.0%)
162 G. Andrikopoulos et al.patients at discharge had reduced EF (<40%) and of whom
75 (8.5%) did not have known heart failure at admission. In
Table 3, we report the medications at hospital discharge
and at follow-up.
3.6. Follow-up
Of the 787 patients who were discharged, 5 were lost in
follow-up, and the exact date of follow-up was not re-
ported for 5 patients. The patients were followed for a
median time of 189 days (IQR: 180e212). During follow-
up, in 99 (12.6%) patients, at least one major adverse
cardiac event (MACE) occurred, and 21 died (2.7%). Spe-
cifically, 5 patients suffered a stroke (0.6%), 9 patients
suffered a myocardial infarction (1.1%), 13 patients
required urgent coronary revascularization (1.7%) and 80
patients were hospitalized (10.2%) urgently for cardio-
vascular causes. NSTEMI/UA patients showed a trend for a
higher incidence of MACE compared with STEMI patients
who was not statistically significant (14.7% vs 10.7%,
pZ0.09). Concerning each endpoint separately, only
stroke was statistically more frequent in NSTEMI/UA pa-
tients compared with STEMI patients (1.3% vs 0%,
pZ0.021).4. Discussion
The PHAETHON study was designed to include a repre-
sentative sample of patients with ACS on a nationwide
basis, aiming to continue and advance the findings from
the “parent” study HELIOS that was published 8 years ago.
The prospective, multicenter, observational PHAETHON
study, which enrolled consecutive patients with a hospital
discharge diagnosis of ACS, was conducted to provide data
regarding the epidemiological pattern, the management
and the outcome of patients with ACS throughout Greece
in real-time hospital conditions and not in the “protected”
setting of randomized clinical trials where tertiary and
university hospitals are overrepresented.
4.1. Baseline characteristics and initial
presentation
Several large-scale, countrywide (nationwide), population
studies in the last 20 years have examined the epidemio-
logical characteristics of patients either with acute MI or,
more recently, ACS. These population studies include the
Hellenic study of acute MI, which recruited almost 7500
Epidemiology of ACS in Greece 163patients withMI fromalmost all the country-wide hospitals in
themid-1990s,10 the CARDIO2000 case-control study of acute
coronary syndromes,11 the prospective GREECS study that
estimated the crude annual incidence rate of ACS in 22.6 per
10,000 people,12 the TARGETstudy,13 the APTOR II study that
focusedmainly on patients undergoing coronary intervention
and their antiplatelet therapy,14 the Stent For Life initiative
that investigated the management of STEMI patients15 and
the HELIOS study.3 Interestingly, in several cases, data from
these studies were used in larger European surveys.2,16e20
The mean presentation age of this study is similar or
somewhat lower comparedwith older surveys. This different
may be attributed to the higher prevalence of cardiovascular
risk factors as well as our better understanding of and
ability to detect ACS (i.e., with the use of high sensitivity
troponin).16 Both genders have similar representation in
STEMI, as well in NSTEMI/UA ACS. Smokers and younger in-
dividuals as observed in the HELIOS study still have a higher
risk for STEMI compared with NSTEMI/UA, implying a much
more aggressive cardiac phenotype in young smokers that
relates to higher in-hospital mortality.10 In contrast, a his-
tory of CAD, hypertension, diabetes, metabolic syndrome
and hypercholesterolemia are more common risk factors in
NSTEMI/UA compared with STEMI patients, implying a more
indolent cardiac phenotype that relates to more severe
complications during follow-up after the initial event,
especially if these risk factors are not well-controlled.
The study elucidates the clinical characteristics of the
“real-world” ACS patient and unveils a deteriorating
burden of cardiovascular risk factors among ACS patients
in Greece. Despite a potential difference in definitions
from earlier studies, the prevalence of the main cardio-
vascular risk factors such as hypertension (59%), hyper-
cholesterolemia (53%), smoking (71%) and diabetes (27%)
remains similar to those previously presented, especially
in the HELIOS study.3 However, the percentage of patients
with a history of CAD has considerably increased from 18%
in HELIOS to 24% in our survey, which was also confirmed
by the TARGET study.13 This finding stresses the increased
cardiovascular risk and overall economic impact due to
frequent hospitalizations of patients with CAD, as well as
the need for better implementation of secondary pre-
vention measures in these patients. Furthermore, in the
present study, patients had a higher BMI compared with
earlier studies, and more than 1 out of 2 ACS patients
(59%) had a metabolic syndrome. This percentage is much
higher to the one (36.2%) described in the CARDIO2000
study,17 underscoring the growth of the obesity epidemic,
which is attributed to lifestyle and nutritional changes.
These findings are essential for physicians and healthcare
policymakers who have the challenging and provoking task
of reducing the obesity epidemic, improper nutrition and
sedentary lifestyle as well as the prevention and early
identification of metabolic syndromes.
In this study, the time from symptom onset to FMC (168
min) was shorter than the time described in HELIOS study3
(180 min) and slightly longer than the time describe in the
Stent for Life study15 (140 min), demonstrating the need for
better patient education, as well as better organization of
the prehospital service. This finding is further confirmed by
the fact that in our study, the patients who chose to use
their own means of transportation instead of the EMS hadshorter transportation times, which is in accordance with
TARGET study13 that showed that the mean waiting time for
and ambulance was approximately 20 minutes and stresses
the need for better organization and increase in manpower
of the EMS. Nevertheless, 1 out of 2 patients used the EMS,
a percentage that is substantially higher than the 38%
percent in STEMI patients in the Stent for Life study.15
4.2. Management of STEMI and NSTEMI/UA patients
Over the past several years, a substantial improvement has
been observed in the management of ACS patients. The
most important element of treatment in STEMI patients still
is the timely implementation of reperfusion therapy, by
either PCI or fibrinolysis, while in NSTEMI/UA patients an
earlier invasive strategy has been advocated. As previously
described,15 a clear increase was observed in the number of
primary PCI procedures in recent years in Greece. This in-
crease is linked to an impressive decrease of the no-
reperfusion option for STEMI. Specifically, in the earlier
HELIOS study,3 9% underwent primary PCI, 50% underwent
fibrinolysis and 41% received no reperfusion therapy, while
in the more recent Stent For Life study,15 32% underwent
primary PCI, 40% underwent fibrinolysis and 28% received no
reperfusion therapy. Similarly, we have shown similar and
somewhat better percentages in the management of STEMI
patients with 34% undergoing primary PCI (39% underwent
coronary angiogram), 44.5% undergoing fibrinolysis and only
16.5% receiving no reperfusion therapy, implying an
improvement in the management of STEMI patients. How-
ever, the main reasons for no reperfusion therapy remain
delayed hospital admission and unavailability of primary
PCI, entailing the improvement of the infrastructure and
participation of PCI networks in a nationwide scale.
As far as NSTEMI/UA patients are concerned, a more
invasive approach was observed in approximately 40% of
patients who underwent coronary angiography in a median
time period of less than 2 days, with 24% of the patients
also undergoing PCI. This finding is an important advance-
ment since the HELIOS study3 in which only 6.1% of NSTEMI
patients underwent coronary angiography and PCI. The
non-invasive approach of stress testing is not preferred
during hospitalization for an ACS, and in most cases, is not
crucial for the management of the NSTEMI/UA patient.
Therefore, in the current practice environment where
coronary catheterization is by far the initial diagnostic
modality in NSTEMI/UA patients, the role of stress testing
warrants further investigation.18
Additionally, an essential differentiation from earlier
studies is that the percentage of patients undergoing coro-
nary angiogram through the radial approach has increased
significantly (approximately 1 out of 5 patients for all ACS
patients) compared with the 2.3% reported in the APTOR II
study,14 showing an important progress in technical skills in
Greece as well as elaborating the lower hospitalization
time.19
4.3. In-hospital complications and mortality
In our study, a relatively high rate of in-hospital compli-
cations was accompanied by a relatively low rate of in-
164 G. Andrikopoulos et al.hospital mortality. This discrepancy has many plausible
explanations. First, the high rate of in-hospital complica-
tions can be partially explained by the extensive list of
minor complications (e.g., atrial fibrillation and angina) as
well as major in-hospital complications (e.g., asystole and
ventricular fibrillation) that was not reported in other
relevant studies.3,13 Moreover, the in-hospital mortality
observed (1.63%) was similar to the one estimated by the
GRACE score for in-hospital mortality (2.05%), suggesting a
small likelihood of selection bias and unreported or missed
events. Furthermore, in our study, most of the patients
underwent reperfusion therapy or were promptly trans-
ferred to larger hospitals,20 diminishing the risk of in-
hospital mortality, compared with older studies that had
high rates of patients with no reperfusion who were
conservatively managed. Invasive management could also
explain the higher rate of minor complications compared
with death because most invasive measures may have
averted death as a complication at the expense of minor
complications. All of these factors elucidate the lower
mortality rate observed compared with the earlier HELIOS3
(7.7% for the total patient population, 8.9% for STEMI and
5.8% for NSTEMI patients) and STENT FOR LIFE15 (4.7% for
STEMI patients undergoing primary PCI, 4% for NSTEMI and
11% no reperfusion patients) studies. However, in more
recent studies, the in-hospital mortality is similar to the
one observed in PHAETHON,13 indicating a slow but steady
reduction of in-hospital mortality in Greece, as well as in
Europe.18,21 Notably, in accordance with larger surveys, we
also found a higher risk of in-hospital complications in pa-
tients with STEMI compared with NSTEMI/UA, confirming
their worse in-hospital prognosis.22
4.4. Hospital discharge and short-term follow-up
For the first time in Greece, an assessment and classifica-
tion of myocardial infarction was performed according to
the recent universal definition of MI.4 Our findings confirm
studies in other European countries that have shown that
despite the extremely high percentage of type 1 MI
(approximately 9 out of 10 cases of MI), a small but sub-
stantial percentage of patients with type 2 MI exists be-
tween 5% and 10%.23 This finding is of extreme importance
because it is now well established that these patients have
a higher risk for future events and should be closely fol-
lowed and intensively managed post discharge.24
Furthermore, primarily due to the immediate invasive
treatment as well as the timely transfer to tertiary hospi-
tal, days of hospitalization have significantly decreased
compared with the TARGET study13 in which patients were
hospitalized for approximately 7 days. However, the
application of more tight economic boundaries in hospi-
talizations has also contributed to this decrease.
The use of beta-blockers, aspirin, statins and angio-
tensin converting enzyme inhibitors (ACE) or angiotensin
receptor blockers (ARBs) at discharge has been utilized for
the evaluation of the standard of care provided and is
considered as an indicator of hospital quality perfor-
mance. In our survey, aspirin was used in 94% of patients
at discharge, while beta-blockers and ACE inhibitors or
ARBs were administered to 86% and 71%, respectively.Concerning the use of statins, an impressive 96% of our
patients received statins upon discharge. Notably, in our
survey, we found an increased rate of use of most types of
evidence-based medications compared with the HELIOS
study.3 Upon discharge, a greater proportion of our pa-
tients were prescribed antiplatelets, beta-blockers and
statins in comparison to the respective ratios reported in
the HELIOS study3; however, a slight decrease in the use
of ACE inhibitors and ARBs was noted. Importantly, this is
the first nationwide study on ACS that shows the entrance
of newer antiplatelets in the management of ACS pa-
tients. Specifically, in accordance with recent European
guidelines, the use of primarily ticagrelor (17%) and, to a
lesser extent, prasugrel (6%), has been introduced in
clinical practice, leading to a reduction of the use of
clopidogrel compared with the results from the TARGET
study (66% from 84%).13 These rates are lower than the
ones reported for the newer antiplatelets in the GRAPE
study.25 However, in GRAPE study, only patients with ACS
from tertiary hospitals undergoing PCI were included.
Thus, we believe that our estimates are closer to the real-
world ACS patient and that these estimates underscore
the need for better adherence to guidelines concerning
antiplatelet use. Thus, the quality measures for the use of
evidence-based medicine that have been shown to
improve patient prognosis demonstrate a satisfactory
hospital performance, which indicates a substantial
improvement in the management of patients and better
adherence to the current guidelines.
Regarding follow-up, our short-term mortality is some-
what lower than the one presented in earlier studies;
however, the mortality is still similar to the one expected
according to the GRACE score (2.7% compared to 3.5%,
respectively). Furthermore, the validity of our follow-up
data is also confirmed by the fact that NSTEMI/UA patients
exhibited a trend for higher incidence compared with STEMI
patients, which is in accordance with larger surveys.
4.5. Limitations
The study has the limitations of an observational study.
Although a large number of consecutive ACS patients were
enrolled, reflecting current practice, not all patients with
ACS admitted to those hospitals were included. Thus, a
small likelihood of selection bias cannot be excluded.
However, in contrast to most previous surveys or registries,
we enrolled a representative sample from the majority of
Greek hospitals with cardiology departments, with a
balanced representation of invasive and non-invasive hos-
pitals, of urban and rural areas. Furthermore, the majority
of our findings were confirmed by larger surveys, suggetsing
that we managed to adequately reflect real-world practice.5. Conclusions
The PHAETHON study was a multicenter, observational
survey that illustrated the epidemiological characteristics,
the management and the outcome of ACS patients in
Greece. Considerable research over the last several years
has produced a better understanding of and compliance to
Epidemiology of ACS in Greece 165evidenced-based management strategies, such as the
timely use of invasive management, which has led to sig-
nificant improvements in the management and outcome of
ACS patients, despite the lack of improvement of the car-
diovascular profile of ACS patients. However, considerable
room for improvement still remains, and many challenges
need to be addressed to improve the prognosis of ACS pa-
tients in Greece.
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